Tetraphase Pharmaceuticals (TTPH) Getting Somewhat Positive Press Coverage, Analysis Shows

Media headlines about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tetraphase Pharmaceuticals earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.9871544869114 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down $0.08 during trading hours on Friday, reaching $2.12. 1,909,900 shares of the company traded hands, compared to its average volume of 1,467,164. Tetraphase Pharmaceuticals has a one year low of $2.10 and a one year high of $9.93. The firm has a market cap of $113.51, a P/E ratio of -0.74 and a beta of 2.29.

TTPH has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 28th. BMO Capital Markets downgraded shares of Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price target on the stock. in a report on Wednesday. Stifel Nicolaus cut their price target on shares of Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, SunTrust Banks reiterated a “buy” rating and issued a $10.00 price target on shares of Tetraphase Pharmaceuticals in a report on Wednesday. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and an average price target of $10.39.

In other news, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $6.22, for a total transaction of $54,425.00. Following the sale, the insider now owns 8,750 shares of the company’s stock, valued at approximately $54,425. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director L Patrick Gage acquired 3,880 shares of the company’s stock in a transaction dated Wednesday, November 29th. The shares were purchased at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the purchase, the director now directly owns 38,880 shares in the company, valued at $250,776. The disclosure for this purchase can be found here. 5.50% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals (TTPH) Getting Somewhat Positive Press Coverage, Analysis Shows” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/17/tetraphase-pharmaceuticals-ttph-getting-somewhat-positive-press-coverage-analysis-shows.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Insider Buying and Selling by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply